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MemorykillerT cells contribute tocontrol of secondaryviral infectionbyexhibiting rapideffector functionupon
reinfection. In this issue of Immunity, Kohlmeier et al. (2010) demonstrate that type I interferon is key for rapid
upregulation of effector function within circulating memory T cells, ensuring efficient control of infection.Activated CD8+ Cytotoxic T lymphocytes
(CTLs) play a key role in the acute control
of most virus infections. As the name
suggests, CTLs are able to recognize
and kill virally infected cells, thereby
removing any potential reservoir for viral
replication. Activated CTLs have cyto-
plasmic granules that contain a spectrum
of cytotoxic proteins, including the pore-
forming protein, perforin (pfp), and an
arrayof serineproteasescalledgranzymes
(grz, granuleenzymes).CTLmediate killing
by depositing the contents of the cyto-
plasmic granules onto the target cell,
whereupon perforin and granzymes work
synergistically to initiate programmed cell
death. Granzymes (grz) B and A are the
most abundant granzymeswithin thecyto-
lytic granules, and their expression is
considered to be a signature of activated
CD8+ T cells (Smyth et al., 2001).
Upon infection, naive, virus-specific
CD8+ T cells are activated and undergo
a program of proliferation and differentia-
tion whereby they increase in number and
start to express signature cytolytic mole-
cules grzB and pfp (Jenkins et al., 2008).
The acquisition of effector gene expres-
sion is tightly linked to antigen-dependent
proliferation, and as such, it takes naive
CD8+ T cells about 2 to 3 days to express
signature cytolytic proteins (Jenkins et al.,
2008). Upon resolution of the infection,
activated CTL numbers contract, leaving
a pool of long-livedmemory T cells. A hall-
mark of adaptive T cell immunity, memory
CTLs provide enhanced protection from
the ravages of a second infection. Key to
this protective capacity, and in contrast
to naive CD8+ T cells, is the ability of
memory CTLs to display immediate
effector function upon recognition of
specific antigen. This is particularly true
of memory T cells found to reside in
peripheral tissues long after the infection
has cleared (Gebhardt et al., 2009; Maso-pust et al., 2001). In contrast, studies have
demonstrated that circulating memory
CTL exhibit little or no expression of cyto-
lytic machinery and display diminished
in vivo and/or ex vivo cytolytic activity
(Jenkins et al., 2007; Masopust et al.,
2001). As such, circulating memory
T cells can be considered quiescent, yet
these same memory CTLs are recruited
quickly to the site of infection and
contribute to early control of virus infec-
tion (Kohlmeier et al., 2008). Thus, a key
question in the field is how do circulating
memory CTLs act so quickly to provide
protection from reinfection when it is clear
that these cells exhibit poor cytolytic
capacity?
Kohmeier et al., (2010) have investi-
gated how these circulating memory
CTLs are able to respond with such
rapidity to secondary viral challenge.
Using non-crossreactivemodels of sendai
and influenza respiratory virus infections
in B6 mice, Kohlmeier et al. (2010) were
able to assess the impact of non-
antigen-specific (influenza virus-induced)
inflammation on pre-existing Sendai-
specific CTL memory populations. Strik-
ingly, respiratory infection with an unre-
lated influenza A virus induced peak grzB
expression within sendai virus-specific
memory CTLs within 2 to 3 days after
infection. Expression of grzB was not
limited to memory CTLs found in the
infected lung but was also observed in
memory CTLs located at distant anatom-
ical sites from the infection. This anti-
gen-independent upregulation of grzB
correlated with superior ex vivo antigen-
specific cytotoxicity compared tomemory
CTLs taken from mock challenged mice.
The rapid and systemic induction of
grzB expression within circulating mem-
ory CTLs pointed to a key role for nonspe-
cific inflammation. It has long been
appreciated that such inflammation,Immuparticularly type I interferon (IFN)
signaling, plays a key role in ensuring
effective primary T cell responses to
infection. Although type I IFN signals
also appear to be important for establish-
ment of robust memory populations (Ko-
lumam et al., 2005), little is known about
their role in promoting recall T cell
responses. In fact, previous work has
suggested that induction of type I IFNs
after heterologous infection results in
attrition of pre-existing memory T cell
numbers (McNally et al., 2001). This has
been proposed as a mechanism for
accommodating newly generated mem-
ory T cell populations in the memory
T cell compartment. Through a series of
bone marrow chimera experiments, Kohl-
meier et al. demonstrate that the nonspe-
cific induction of granzyme B expression
and enhanced cytolytic ability were
dependent on STAT 1 transcription factor
signaling and, specifically, signaling
through the type I IFN receptor. That
type I IFN signaling was both necessary
and sufficient to upregulate granzyme B
was evidenced by the enhanced expres-
sion of granzyme B after addition of
IFN-a or IFN-b to memory CTLs from
mice or to cultures of human peripheral
blood mononuclear cells. Thus, the
phenomena of upregulated granzyme B
expression along with enhanced cytolytic
ability as a consequence of type I inter-
feron signaling are convincingly estab-
lished in this study (Figure 1).
Critically, however, theconsequencesof
the burgeoning cytolytic potential implied
by the earlier experiments, and the real
physiological relevance of these phe-
nomena, are only revealed when the
established memory population was
primed and challenged with antigenically
related viruses. This enabled the conse-
quenceofnonspecificeffectsof the inflam-
matory environment on antigen-specificnity 33, July 23, 2010 ª2010 Elsevier Inc. 5
Figure 1. Type I IFN Signaling Induces Immediate Cytolytic Capacity in Circulating Memory
CTL
Upon secondary influenza infection, systemic inflammatory signals are induced that include production of
type I interferons (IFN). The lung-resident memory CTLs, while able to provide some control of infection,
are not cytolytic. Circulating memory CTLs do not express granzyme B and are, hence, noncytolytic
(unarmed). Signaling via systemic type I IFN induces antigen-independent granzyme B protein expression
within circulating memory CTLs and imparts cytolytic function. These ‘‘armed’’ CTLs are then recruited to
site of infection where they help limit viral replication.
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mined. In this elegant set of experiments,
chimeric mice that had received bone
marrow from either wild-type or Ifnar1/
mice were primed and challenged with
related influenza viruses. Despite the
ability of all memory CTLs to recognize
specific antigen, wild-type memory CTLs
showed substantially elevated amounts
of granzyme B after challenge compared
to Ifnar1/ cells. Furthermore, this differ-
ence corresponded to substantially lower
viral titers 3 days after influenza challenge.
As such, these data convincingly explain
how memory CTLs recruited to the site of
infection are able to respond with such
rapidity after secondary infection.
Kohlmeier et al. demonstrate that the
rapid cytolytic response that is a conse-
quence of priming by type I IFN signaling
appears limited to cells entering the
affected tissue from the circulation and
not those resident in the lungs. Their
data clearly show that tissue resident
memory cells (as defined by low expres-
sion of CD11a) exhibit only a modest
increase in granzyme B expression and
remain poorly cytolytic compared to6 Immunity 33, July 23, 2010 ª2010 Elseviermemory cells entering the lungs after
challenge. These data appear contradic-
tory to earlier studies by this group (Hogan
et al., 2001) and others (Gebhardt et al.,
2009; Masopust et al., 2001) that have
demonstrated the protective capacity of
tissue resident memory CTLs. It is also is
in direct contrast to earlier studies that
have demonstrated tissue-resident virus-
specific memory CTL established in
models of Listeria monocytogenes, vesic-
ular stomatits virus, or herpes simplex
virus do, in fact, exhibit enhanced cyto-
lytic activity compared to circulating
memory T cells (Gebhardt et al., 2009;
Masopust et al., 2001). The reasons for
these differences are unclear and suggest
that the route of infection or the type of
pathogen may influence the expression
of type I IFN receptors by the CTLs. This
needs to be assessed in these models of
nonrespiratory infection. Moreover, it is
possible the lung microenvironment may
actively suppress cytolytic activity by
tissue-resident memory CTLs. It makes
sense to ensure that such a potent
effector mechanism is tightly controlled
in such a sensitive tissue. Thus, this studyInc.indicates that the protection afforded by
tissue-resident memory CTLs is mediated
by noncytolytic functions; however, the
precise mechanism remains to be deter-
mined. Similarly, how these two popula-
tions of memory cells, circulating and
resident, act in concert to promote viral
clearance remains to be elucidated.
Finally, understanding the events that
render memory T cells responsive to
type I IFN signaling and, therefore, more
rapid responses will be key for improving
strategies designed to promote effective
cellular immunity.
In summary, this study provides an
intriguing solution to the quandary of
how resting memory cells react so quickly
after antigen re-encounter. Unlike quies-
cent naive cells, whose acquisition of
cytolytic capacity is only initiated upon
antigen recognition, circulating memory
cells are alerted to the presence of infec-
tion, allowing them to arm themselves
prior to antigen encounter. This prime
example of collaboration between innate
and adaptive immunity thus epitomizes
the adage ‘‘forewarned is forearmed.’’REFERENCES
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